Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
2.02B | 1.90B | 1.79B | 1.68B | 1.50B | Gross Profit |
635.54M | 595.43M | 553.23M | 542.40M | 454.51M | EBIT |
139.79M | 8.07M | 26.30M | 95.97M | 81.95M | EBITDA |
187.38M | 44.35M | -517.28M | -9.26M | 22.13M | Net Income Common Stockholders |
-10.93M | -134.52M | -662.03M | -117.04M | -57.05M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
84.29M | 43.94M | 19.22M | 30.49M | 137.34M | Total Assets |
1.66B | 1.61B | 1.71B | 2.33B | 1.84B | Total Debt |
1.33B | 1.50B | 1.36B | 1.30B | 1.23B | Net Debt |
1.24B | 1.46B | 1.34B | 1.27B | 1.09B | Total Liabilities |
1.79B | 1.74B | 1.72B | 1.70B | 1.58B | Stockholders Equity |
-122.09M | -127.44M | -4.17M | 637.95M | 267.17M |
Cash Flow | Free Cash Flow | |||
26.32M | 16.56M | -60.41M | -27.30M | 101.38M | Operating Cash Flow |
32.64M | 22.67M | -48.40M | -11.35M | 116.62M | Investing Cash Flow |
-6.32M | -8.79M | -25.29M | -681.83M | -193.54M | Financing Cash Flow |
14.03M | 10.85M | 62.42M | 586.33M | 210.94M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
73 Outperform | $1.05B | 25.71 | 8.37% | ― | 3.71% | 1.32% | |
70 Outperform | $931.95M | 37.96 | 11.28% | ― | 30.04% | 43.47% | |
67 Neutral | $1.09B | 39.24 | 6.72% | 2.39% | 14.30% | 76.89% | |
54 Neutral | $747.97M | 18.62 | -21.08% | ― | -18.13% | -215.78% | |
54 Neutral | $1.58B | ― | -91.17% | ― | 3.88% | -34.30% | |
52 Neutral | $5.15B | 3.56 | -42.52% | 2.83% | 14.56% | -0.53% | |
50 Neutral | $934.50M | ― | 42.49% | ― | 9.05% | ― |
On May 9, 2025, Aveanna Healthcare Holdings Inc. conducted its 2025 Annual Meeting of Stockholders. During the meeting, three Class I directors were elected to the Board for three-year terms, Ernst & Young LLP was ratified as the independent public accounting firm for the fiscal year ending January 3, 2026, and a non-binding advisory resolution on executive compensation was approved. No other matters were addressed at the meeting.
Spark’s Take on AVAH Stock
According to Spark, TipRanks’ AI Analyst, AVAH is a Neutral.
Aveanna Healthcare Holdings is experiencing revenue growth and improved cash flow management, with positive guidance from recent earnings calls. However, persistent financial instability, high leverage, and valuation concerns weigh on the stock’s outlook. The technical analysis shows neutral market sentiment, suggesting a cautious approach is warranted.
To see Spark’s full report on AVAH stock, click here.
On May 9, 2025, Aveanna Healthcare Holdings Inc. released a financial presentation to investors, emphasizing the company’s use of its website as a primary channel for distributing important information. The presentation highlighted Aveanna’s financial performance and operational statistics, including over $2.15 billion in revenue and a significant presence across 34 states with 26,500 caregivers. The company continues to focus on growth strategies and maintaining a diverse payor mix, which is crucial for its financial stability and market positioning.
Spark’s Take on AVAH Stock
According to Spark, TipRanks’ AI Analyst, AVAH is a Neutral.
Aveanna Healthcare Holdings shows growth in revenue and cash flow but faces significant financial instability due to high leverage and consistent net losses. Technical analysis is neutral, with limited positive momentum. Valuation concerns persist due to a negative P/E ratio. The earnings call and corporate events provide a cautiously optimistic outlook, but substantial challenges remain, impacting the overall stock score.
To see Spark’s full report on AVAH stock, click here.
Aveanna Healthcare Holdings reported a strong financial performance for the first quarter of 2025, with a 14.0% increase in revenue to $559.2 million and a significant rise in adjusted EBITDA by 93.1% compared to the previous year. The company also revised its full-year 2025 revenue guidance to exceed $2.15 billion and adjusted EBITDA to surpass $207 million, reflecting positive momentum and strategic transformations, including successful cost reductions and improved reimbursement rates.
Spark’s Take on AVAH Stock
According to Spark, TipRanks’ AI Analyst, AVAH is a Neutral.
Aveanna Healthcare Holdings demonstrates revenue growth and improving cash flow, yet struggles with high leverage and consistent net losses. The technical outlook is neutral, and valuation metrics are concerning. The earnings call highlights strategic initiatives for future growth, but labor market challenges and muted segment growth present risks. Overall, the stock’s performance is hindered by financial instability and valuation concerns.
To see Spark’s full report on AVAH stock, click here.
On March 27, 2025, Dr. Sheldon Retchin, a Class III Director of Aveanna Healthcare Holdings Inc., resigned from the Board of Directors due to personal health reasons. His departure was not related to any disagreements with the company’s operations or policies. Dr. Retchin was an independent director and served on both the Audit Committee and as Chair of the Clinical Quality Committee.
On March 14, 2025, Aveanna Healthcare Holdings released a financial presentation to investors, highlighting key operational statistics and financial guidance for 2025. The company projects revenues between $2.10 billion and $2.12 billion, with an adjusted EBITDA of $190 million to $194 million. Aveanna operates 341 locations with 26,500 caregivers, delivering 41.6 million homecare hours. The company emphasizes its strategic use of its website for distributing important information, underscoring its commitment to transparency and timely communication with stakeholders.
Aveanna Healthcare Holdings reported strong financial results for the fourth quarter and full year of 2024, with a notable 8.6% increase in revenue to $519.9 million and a significant rise in adjusted EBITDA by 42.8% compared to the previous year. The company also provided a positive outlook for 2025, expecting revenue between $2.10 and $2.12 billion and adjusted EBITDA between $190 and $194 million, driven by strategic cost reductions and enhanced government and payor partnerships.